Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity. 2019

Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, S.A.S Nagar, Punjab, 160062, India.

We report herein the synthesis and anticancer activity of a set of novel S-linked artemisinins bearing an aliphatic/aromatic/heterocyclic nucleus as a substituent on the sulfur. The compounds were prepared from artemisinin via its lactol-form by an acid-catalyzed condensation of the desired thiol with the lactol. Both the C-10-α- and β-configured thiol ethers were synthesized with a view to making them available for the anticancer activity evaluation using a variety of cell lines. The results show that many of the synthetic derivatives studied possessed good potential as anticancer agents. In order to draw more information on the origin of the anticancer activity, one of the compounds (9a), that showed a broad-spectrum activity in terms of reducing the viability of most of the cell lines studied, in particular proven to be most effective against Prostate (PC-3) cells, was studied in detail to find the underlying mechanism of its action by MTT assay, immunoblotting, flow cytometry and microscopy. Pretreatment of the PC-3 cells with N-acetyl cysteine affected the efficacy of 9a, suggesting the role of reactive oxygen species in reducing their viability. Cell cycle analysis showed increase in G1 phase that was indicative of G1 cell cycle arrest. Wound healing assay revealed anti-migratory effect of 9a Quantitative PCR and western blot analysis showed changes in the gene expression of PCNA, E2F1, Pin1, cyclinD1, phospho-c-jun, c-Myc, eIF4E and other genes involved in proliferation and maintaining the transformed phenotype of prostate cancer cells. Here we report the anti-proliferative property of 9a with a vital and potent target(s) in prostate cancer cells with one of such targets being Pin1 belonging to the parvulin family of PPIases. The results suggest that 9a could be a promising agent in combating prostate cancer.

UI MeSH Term Description Entries
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078722 PC-3 Cells An epithelial cell line initiated from a human bone metastasis of a grade IV prostatic ADENOCARCINOMA. Human Prostatic Carcinoma Cell Line PC3,PC-3 (Human Prostatic Carcinoma) Cell Line,PC-3 Cell Line,PC3 Cell Line,PC3 Cells,Cell Line, PC-3,Cell Line, PC3,Cells, PC-3,Cells, PC3,Line, PC-3 Cell,PC 3 Cell Line,PC 3 Cells,PC-3 Cell
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
January 2022, Frontiers in pharmacology,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
February 2012, European journal of medicinal chemistry,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
January 2019, Frontiers in oncology,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
May 2019, Archiv der Pharmazie,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
February 2020, Turkish journal of pharmaceutical sciences,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
January 2013, Scientia pharmaceutica,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
November 2011, European journal of medicinal chemistry,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
August 2019, Molecules (Basel, Switzerland),
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
January 2012, Natural product research,
Rajesh Gour, and Faiz Ahmad, and Santosh Kumar Prajapati, and Santosh Kumar Giri, and Shibendra Kumar Lal Karna, and K P Ravindranathan Kartha, and Yuba Raj Pokharel
February 2010, European journal of medicinal chemistry,
Copied contents to your clipboard!